In this episode, we explore the complex and often debated concept of value in prescription drugs. They discuss how different stakeholders—payers, manufacturers, providers, regulators, and patients—define value, and how methodologies like health technology assessments (HTA) and cost-effectiveness analyses shape drug pricing and access. With insights from leading experts, the conversation examines the controversies surrounding value-based pricing, including the role of real-world evidence, quality-adjusted life years (QALYs), and innovation incentives. Can we strike a balance between affordability, innovation, and patient access? And what does the future hold for value-based drug pricing in the U.S.? Tune in for a deep dive into one of the most critical issues in healthcare today.

• Daniel Ollendorf, Chief Scientific Officer and Director of HTA Methods and Engagement

• Lou Garrison, Professor Emeritus at University of Washington CHOICE

• Institute for Clinical and Economic Review (ICER)
• FDA
• GLP-1 Drugs
• Medicare
• Biosimilars
• Generics Versus Biosimilars
• PBMs (Pharmacy Benefit Managers)

• 340B Drug Pricing Program

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.